Late mortality after hematopoietic SCT for a childhood malignancy

Bone Marrow Transplantation

Volumn 48, Issue 10, 2013, Pages 1291-1295

  Schechter, T ^a   Pole, J D ^a   Darmawikarta, D ^a   Doyle, J ^a   Ali, M ^a   Egeler, M ^a   Gassas, A ^a   Irwin, M S ^a   Greenberg, M ^a   Nathan, P C ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

late mortality; pediatric; SCT

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; METHOTREXATE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANADA; CANCER RECURRENCE; CANCER SURVIVAL; CANCER SURVIVOR; CAUSE OF DEATH; CHILD; CHILDHOOD CANCER; CHRONIC GRAFT VERSUS HOST DISEASE; FATALITY; FEMALE; GENDER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; INFECTION; LATE MORTALITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROBLASTOMA; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RESPIRATORY FAILURE; RISK FACTOR; SCHOOL CHILD; SECOND CANCER; SEIZURE; SURVIVAL TIME;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; ONTARIO; SURVIVAL ANALYSIS; SURVIVORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885676569     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.64     Document Type: Article

References (20)

1. Socie G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999; 341: 14-21. (Pubitemid 29293715)
2. Martin PJ, Counts Jr. GW, Appelbaum FR, Lee SJ, Sanders JE, Deeg HJ et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010; 28: 1011-1016.
3. Bhatia S, Francisco L, Carter A, Sun CL, Baker KS, Gurney JG et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of longterm survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007; 110: 3784-3792. (Pubitemid 350159650)
4. Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29: 2230-2239.
5. Bjorklund A, Aschan J, Labopin M, Remberger M, Ringden O, Winiarski J et al. Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 40: 1055-1062. (Pubitemid 350142559)
6. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 2009; 27: 1007-1013.
7. Jantunen E, Itala M, Siitonen T, Koivunen E, Leppa S, Juvonen E et al. Late nonrelapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1, 482 patients transplanted in 1990-2003. Eur J Haematol 2006; 77: 114-119.
8. Lawitschka A, Ball L, Peters C. Nonpharmacologic treatment of chronic graftversus-host disease in children and adolescents. Biol Blood Marrow Transplant 2012; 18(1 Suppl): S74-S81.
9. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. Cancer 2005; 103: 1457-1467. (Pubitemid 40410743)
10. Liddell FD. Simple exact analysis of the standardised mortality ratio. J Epidemiol Community Health 1984; 38: 85-88. (Pubitemid 14155849)
11. Bhatia S. Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up. Expert Rev Hematol 2011; 4: 437-452, quiz 453-454.
12. Bhatia S, Robison LL, Francisco L, Carter A, Liu Y, Grant M et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 2005; 105: 4215-4222. (Pubitemid 40720765)
13. Robin M, Porcher R, De Castro Araujo R, de Latour RP, Devergie A, Rocha V et al. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor. Biol Blood Marrow Transplant 2007; 13: 1304-1312. (Pubitemid 47571032)
14. Kalhs P, Panzer S, Kletter K, Minar E, Stain-Kos M, Walter R et al. Functional asplenia after bone marrow transplantation. A late complication related to extensive chronic graft-versus-host disease. Ann Intern Med 1988; 109: 461-464.
15. Socie G, Salooja N, Cohen A, Rovelli A, Carreras E, Locasciulli A et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003; 101: 3373-3385. (Pubitemid 36857917)
16. Abou-Mourad YR, Lau BC, Barnett MJ, Forrest DL, Hogge DE, Nantel SH et al. Longterm outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplant 2010; 45: 295-302.
17. Bieri S, Roosnek E, Ozsahin H, Huguet S, Ansari M, Trombetti A et al. Outcome and risk factors for late-onset complications 24 months beyond allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2011; 87: 138-147.
18. Jacobsohn DA, Arora M, Klein JP, Hassebroek A, Flowers ME, Cutler CS et al. Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease. Blood 2011; 118: 4472-4479.
19. Kushner BH, Cheung NK, Kramer K, Heller G, Jhanwar SC. Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 1998; 16: 3880-3889. (Pubitemid 29001542)
20. Kushner BH, Kramer K, Modak S, Qin LX, Yataghena K, Jhanwar SC et al. Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma. Pediatr Blood Cancer 2009; 53: 17-22.